SCAFFOLDED NUCLEIC ACID POLYMER PARTICLES AND METHODS OF MAKING AND USING
    23.
    发明申请
    SCAFFOLDED NUCLEIC ACID POLYMER PARTICLES AND METHODS OF MAKING AND USING 有权
    SCAFFEDED核酸聚合物颗粒及其制备和使用方法

    公开(公告)号:US20100304982A1

    公开(公告)日:2010-12-02

    申请号:US12785685

    申请日:2010-05-24

    Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.

    Abstract translation: 本发明提供了在核酸分析中具有应用的颗粒组合物。 本发明的核酸聚合物颗粒允许多核苷酸在其整个体积中被连接,以便比仅通过表面附着可实现的更高的负载能力。 在一个方面,本发明的核酸聚合物颗粒包含具有低变异系数的具有均匀尺寸分布的聚丙烯酰胺颗粒,这导致分析测定中粒子与粒子变化的减少。 这种颗粒组合物用于各种扩增反应以制备来自核酸片段文库的扩增子文库。

    NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS
    25.
    发明申请
    NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS 失效
    新型组织因子靶向的血栓调节蛋白融合蛋白作为抗凝剂

    公开(公告)号:US20080020965A1

    公开(公告)日:2008-01-24

    申请号:US11766160

    申请日:2007-06-21

    Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

    Abstract translation: 本发明涉及新颖的融合蛋白,其由结合组织因子(TF)的靶向蛋白组成,其与单独的血栓调节蛋白EGF456结构域或与至少一种其它TM结构域可操作地连接,所述TM结构域选自 的N末端疏水区域,EGF123结构域,EGF3和EGF4之间的域间环和O-糖基化的Ser / Thr富集结构域,或其类似物,片段,衍生物或变体。 融合蛋白在损伤位点处结合并防止血栓形成的发生。 融合蛋白可用于治疗各种血栓形成病症,包括但不限于深静脉血栓形成,弥散性血管内凝血和急性冠状动脉综合征。

Patent Agency Ranking